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Halipd, Tudor Opreab,c, Anna Wallerb, Mark B. Carterb, Yinan Zhange, Wei Wangf, Tione Burandaa, 
and Larry A. Sklara,b
aDepartment of Pathology and Cancer Center, bUniversity of New Mexico Center for Molecular Discovery, and 
cDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131; 
dDepartment of Computational Chemistry, Institute of Chemistry, Romanian Academy, Timisoara 300223, Romania; 
eDepartment of Pharmaceutical Science, College of Pharmacy, University of Kentucky, Lexington, KY 40506; 
fDepartment of Chemistry, University of New Mexico, Albuquerque, NM 87131
ABSTRACT Lymphocyte function–associated antigen 1 (LFA-1, CD11a/CD18, αLβ2-integrin) 
and its ligands are essential for adhesion between T-cells and antigen-presenting cells, forma-
tion of the immunological synapse, and other immune cell interactions. LFA-1 function is 
regulated through conformational changes that include the modulation of ligand binding af-
finity and molecular extension. However, the relationship between molecular conformation 
and function is unclear. Here fluorescence resonance energy transfer (FRET) with new LFA-
1–specific fluorescent probes showed that triggering of the pathway used for T-cell activation 
induced rapid unquenching of the FRET signal consistent with extension of the molecule. 
Analysis of the FRET quenching at rest revealed an unexpected result that can be interpreted 
as a previously unknown LFA-1 conformation.
INTRODUCTION
LFA-1 plays a significant role in the pathogenesis of numerous au-
toimmune and inflammatory diseases (Yusuf-Makagiansar et al., 
2002; Hyun et al., 2009). Blocking integrin-dependent adhesion 
and using LFA-1 as a target for drug delivery represent possible 
therapeutic approaches in the treatment of multiple hematologic 
malignancies (Schmidmaier and Baumann, 2008; Phongpradist 
et al., 2010). Therefore our understanding of LFA-1 physiology 
is essential for the success of future LFA-1–related therapeutic 
applications.
LFA-1–dependent cell adhesion is regulated by a series of confor-
mational changes within the molecule that are induced by signaling 
triggered by other cell receptors. Numerous immune receptor li-
gands, chemoattractants, and chemokines can initiate this so-called 
“inside-out” signaling cascade (Laudanna et al., 2002; Alon and 
Feigelson, 2009; Zarbock and Ley, 2009). This pathway serves as a 
basis for cell adhesion, retention, and chemotaxis toward sites of in-
flammation and secondary lymphoid tissues (Ley et al., 2007). Integ-
rin activation represents a mechanism for the arrest of rolling leuko-
cytes on the endothelial surface under shear flow (Laudanna and 
Alon, 2006). A model for rapid LFA-1 integrin activation includes at 
least three conformations: folded (bent) low affinity, extended low or 
intermediate affinity, and extended high affinity (Laudanna and Alon, 
2006; Hogg et al., 2011). LFA-1 extension is implicated in LFA-1–
mediated rolling (Salas et al., 2004, 2006; Chigaev and Sklar, 2012a).
Previously we developed a fluorescence resonance energy 
transfer (FRET)–based approach for studying molecular extension 
of another leukocyte integrin, very late antigen-4 (VLA-4), on live 
cells and in real time (see Figure 1 in Chigaev et al., 2007; also see 
Chigaev et al., 2003). This approach has been used to identify sev-
eral previously unknown VLA-4 conformations (Chigaev et al., 2007, 
2009) and decode the complexity of VLA-4 conformational regula-
tion through “inside-out” signaling pathways (Chigaev et al., 2008; 
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allosteric antagonists (Shimaoka and 
Springer, 2003). The BIRT 377 binding site is 
located within the I domain of the αL integ-
rin subunit, and it binds in the hydrophobic 
pocket underneath the C-terminal α-helix 
(Figure 2). The XVA-143 site is located be-
tween the αL β-propeller and the β2 subunit 
I–like domain. To estimate the distance be-
tween the two ligand-binding sites, we built 
a three-dimensional (3D) homology model 
of the LFA-1 structure and placed two allos-
teric antagonists into the binding sites. The 
crystal structure of the complex of the LFA-1 
(CD11a) αL I domain with lovastatin (Protein 
Data Bank: 1CQP) was used as a template 
for placement of both BIRT 377 and XVA-
143 ligands. We used the Molecular Operat-
ing Environment (MOE) software to estimate 
the distance between these two ligands 
(Figure 2). Because the estimate obtained 
(∼43 Å) was comparable to the Förster dis-
tance (R0) for the fluorescein–rhodamine 
FRET pair (55 Å; Chigaev et al., 2003, and 
references therein), we compared FRET be-
tween fluorescein-conjugated analogues of 
BIRT 377 and XVA-143 and membrane-in-
corporated lipid acceptors, as was done 
previously for VLA-4 (Chigaev et al., 2003, 
2007). We hypothesized that the difference 
in the distance between probe binding sites 
would directly affect the distance of closest 
approach (rc) to the cell membrane. Thus 
FRET could serve as an “intramolecular 
ruler” to provide information about relative 
positions of the probes in different integrin 
activation states (Figure 2).
The quenching kinetics of XVA– and BIRT–fluorescein 
isothiocyanate at rest (without activation) revealed a 
dramatic difference
Previously, to perform real-time FRET assays, we used octadecyl 
rhodamine B as an acceptor that incorporates into the plasma mem-
brane and induces rapid probe quenching. However, as a single-
chain lipid, it has a tendency to undergo rapid flip-flop between the 
outer and inner leaflets, as well as get internalized in the cytosolic 
space. A reduction in acceptor density in the outer leaflet results in 
the gradual diminution of FRET over time, with a half-time of ∼10 
min (Chigaev et al., 2003). To overcome this limitation, we tested a 
number of fluorescent lipids and selected PKH26, a dye sold by 
Sigma-Aldrich (St. Louis, MO). It has two C18 chains (Figure 1), ex-
hibits appropriate absorption characteristics, and provides a better 
stability of signal.
Addition of saturating concentrations of the donor probes in-
duced rapid probe binding, which reached equilibrium within 2–3 
min. Addition of PKH26 resulted in quenching of both probes. 
However, the real-time kinetics was dramatically different. For XVA–
fluorescein isothiocyanate (FITC), quenching reached its maximum 
during the first minute after the addition of lipid acceptor. For the 
BIRT-FITC probe, quenching required several minutes (Figure 3). 
The difference between the quenching kinetics for BIRT 377 and 
XVA-143 fluorescein-conjugated analogues was maintained over a 
range of PKH26 concentration (0.25–4 μM; Figure 3, C and D).
Chigaev and Sklar, 2012a). The present work provides the first de-
scription of a novel FRET-based methodology for detecting the 
molecular extension of LFA-1 that includes a set of novel fluorescent 
probes, based on use of the LFA-1–specific allosteric antagonists 
BIRT 377 and XVA-143 and a novel lipid acceptor probe. A real-
time flow cytometry approach allowed us to conduct experiments 
on live cells and at natural receptor abundance. No transfected cells 
or engineered or overexpressed proteins were used in this study.
Because the distance between ligand-binding sites for the two 
probes is comparable to the Förster distance for the two fluorophores, 
we detected a significant difference between quenching kinetics for 
BIRT 377– and XVA-143–based probes. Very rapid signal quenching 
detected for the XVA-143–based probe suggests that at rest, without 
cell activation, the XVA-143 ligand-binding site is located in close 
proximity to the membrane. Triggering the signaling pathway relevant 
to the activation of T-cells induced rapid unquenching of the FRET 
signal, which is consistent with rapid extension of the molecule. The 
extension was found to be calcium dependent. Thus the FRET-based 
LFA-1 extension assay provides essential information for our under-
standing of LFA-1 conformational regulation of leukocyte adhesion.
RESULTS
FRET probes binding sites
BIRT 377 and XVA-143 (Figure 1) belong to two distinct classes of 
allosteric antagonists, α I allosteric antagonists and α/β I–like 
FIGURE 1: Structure of LFA-1 allosteric antagonist–based fluorescent probe donors and FRET 
acceptor. (A) BIRT-FITC and (B) XVA-FITC donor probes were designed and synthesized at the 
Department of Chemistry and Chemical Biology, University of New Mexico, by Y.Z. and W.W. 
Allosteric antagonist moieties are indicated in blue. Fluorescein moiety is shown in green. (C) The 
structure of PKH 26 fluorescent dye used as FRET acceptor is not available from Sigma-Aldridge; 
however, according to Life Technologies, the PKH 26 dye is structurally identical to DiIC18(3), 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate, shown in the figure.
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and B). No significant change was detected. 
Thus the addition of unlabeled XVA-143 and 
BIRT 377 had no significant effect on the 
real-time quenching kinetics of BIRT-FITC 
and XVA-FITC probes, respectively.
Finally, because the integrin state, medi-
ated by receptor cytoplasmic domains, de-
pends on active cellular metabolism (O’Toole 
et al., 1994), we treated cells with the mix-
ture of metabolic inhibitors, sodium azide, 
and 2-deoxy-d-glucose. In our experience 
(unpublished data), this mixture rapidly 
down-regulates the affinity of activated 
VLA-4 to its resting state. No significant ef-
fect on the quenching kinetics of XVA-FITC 
or BIRT-FITC was detected (Figure 4C). In all 
experiments, the initial rate of XVA-FITC 
quenching was faster than for BIRT-FITC. 
Thus the difference in the kinetics of the 
LFA-1xspecific ligand quenching was inde-
pendent of the presence of unlabeled XVA-
143 and BIRT 377 or cellular metabolism.
Estimated difference between the 
distances of closest approach for 
XVA-143 and BIRT 377 at rest is similar 
to the distance between the two 
ligand-binding sites
In our experiments, addition of PKH26 as 
the FRET acceptor to the cell suspension 
results in rapid partitioning of the molecules 
into the cell membrane. This process can 
be monitored in FL2 (the red fluorescence 
channel of the FACScan) and did not reach 
equilibrium for >∼5000 s. Therefore a real-
time quenching curve represents a loss of 
donor fluorescence induced by an increas-
ing acceptor surface density over time due 
to continuous acceptor incorporation. Be-
cause we are focusing on the initial time 
interval after PKH26 addition, acceptor incorporation can be con-
sidered linear. A precise quantitative determination of the acceptor 
density (ac/R02) in the vicinity of a particular receptor represents a 
complex task, in part due to membrane heterogeneity (Buranda 
et al., 2010). However, assuming that membrane lipid incorpora-
tion is not significantly affected by the binding of small ligands, in 
which the binding sites have no direct membrane contact (Figure 
2), we can use the difference in the initial quenching rates to esti-
mate the relative difference in the distance of closest approach.
We plotted energy transfer as a function of acceptor density for 
multiple distances of closest approach expressed in terms of the 
Förster distance (rc/R0) according to the calculations of Wolber and 
Hudson (1979; see later discussion of Eq. 4; Figure 5A). Next we 
evaluated the initial rates of acceptor quenching as the slopes of the 
dashed lines for every distance of closest approach. We then nor-
malized slopes relative to the slope of the line corresponding to 0R0 
or 0.7R0 distance (rc/R0 = 0 or 0.7, slope = 1) and show them below 
the graph in Figure 5A.
To estimate the relative initial rates of acceptor quenching in 
cells, we used real-time quenching curves. Because the Wolber 
and Hudson model is only valid for acceptor densities <0.5 
acceptor/R02, we focused on the analysis of the early quenching 
Quenching kinetics of XVA- and BIRT-FITC was independent 
of the other allosteric antagonist and cell metabolic activity
The unexpected difference in the quenching kinetics of XVA-FITC 
and BIRT-FITC probes promoted a series of experiments aimed at 
identifying possible reasons for this observation. Because energy 
transfer depends on the distance of closest approach between the 
FRET donor and acceptor and does not discriminate vertical and 
horizontal probe separation, lateral probe segregation or partition-
ing into different phases of lipids could directly affect quenching 
efficiency (Buranda et al., 2010). However, because both probes are 
targeting the same receptor on the cell surface (LFA-1), selective 
lipid acceptor segregation is unlikely.
Another possibility is that ligands by themselves can actively affect 
integrin conformation. Based on cell rolling data and epitope expo-
sure, it has been proposed that XVA-143 induces an extended con-
formation of LFA-1 (Salas et al., 2004), whereas BIRT 377 blocks the 
induction of the mAb24-activated integrin reporter epitope and sta-
bilizes a bent, low-intermediate affinity conformation (Woska et al., 
2001; Larson et al., 2005; Green et al., 2006). To study the effect of 
XVA-143 on BIRT-FITC quenching kinetics and vice versa, we sequen-
tially treated cells with the fluorescent ligand as donor and a large 
excess (10-fold) of the unlabeled allosteric antagonists (Figure 4, A 
FIGURE 2: Homology model of LFA-1 integrin in bent and extended conformations built as 
described in Materials and Methods. LFA-1 domains are colored and labeled according to 
Shimaoka and Springer (2003). Two allosteric antagonists placed into the corresponding binding 
sites shown as gray and red space-filling models are highlighted by a red circle for BIRT 377 and 
a blue circle for XVA-143. The distance between antagonist binding sites (42.92 Å) is shown. The 
distances of closest approach (rc) between PKH 26 acceptors (shown schematically) incorporated 
into the membrane and donor probes are shown using arrows. For fully extended LFA-1, rc can 
be >200 Å. I-EGF, integrin-epidermal growth factor domain; PSI, plexin/semaphorin/integrin 
domain.
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served difference in the quenching slopes 
can be attributed to the relative distance of 
(0.6–1)R0. With R0 in the range 50–55 Å, this 
puts an estimated difference between dis-
tances of closest approach for XVA-143 and 
BIRT 377 close to the estimate obtained us-
ing the 3D structure of LFA-1 model (∼43 Å). 
Thus the experimentally observed differ-
ence in the initial slopes of quenching curves 
for BIRT-FITC and XVA-FITC can be attrib-
uted to the distance between probe bind-
ing sites.
These data provide insight into the posi-
tion of the LFA-1 I domain on the surface of 
resting cells. According to the current model 
of LFA-1 conformation, the αL I domain po-
sition is envisioned as being aligned with the 
β2 subunit I–like domain (Figure 2) specifi-
cally because of a direct involvement of the 
C-terminal I domain α7-helix and so-called 
intrinsic (endogenous) ligand in the regula-
tion of the αL I domain conformation (Alonso 
et al., 2002; Shimaoka and Springer, 2004). 
However, the resting integrin state with an 
inactive I-like domain and free intrinsic li-
gand creates the possibility for αL I domain 
flexibility (Figure 5C). Such a conformation 
could explain the difference in the initial 
slopes of quenching curves when the dis-
tance of closest approach between the BIRT 
377 binding site and cell membrane (rc2) is 
larger than the distance of closest approach 
for XVA-143 (rc1) by ∼(0.6–1)R0.
Inside-out cell activation results in the unquenching of the 
donor signal for both allosteric antagonist-based probes
LFA-1 activation is known to be regulated through inside-out sig-
naling by intracellular pathways. The signaling occurs through the 
cytoplasmic domain and creates multiple conformational states. 
The molecular extension (unbending) is believed to represent one 
of the major events that lead to rapid and reversible changes in 
cellular adhesive properties. For LFA-1, the extended conforma-
tion is envisioned as a part of intermediate- and high-affinity states 
(Lefort and Ley, 2012). It can be observed, for example, using 
transmission electron microscopy with engineered purified integ-
rins (Nishida et al., 2006). To our knowledge, no prior reports dem-
onstrate an extension of naturally expressed, unmodified LFA-1 
integrin on live cells in real time.
To determine whether integrin conformation could be affected 
by inside-out signaling, we used the human T-cell acute lympho-
blastic leukemia cell line. This line can be activated by a mixture 
of phorbol ester (12-O-tetradecanoylphorbol-13-acetate [TPA]) in 
combination with thapsigargin (TG) or other Ca2+-elevating agent 
(Lyubchenko et al., 2001). This drug combination is a substitute 
for T-cell stimulation via the T-cell receptor (TCR)/CD3 T-cell–spe-
cific signaling pathway, and either compound alone is not suffi-
cient to induce full activation (Lyubchenko et al., 2001; and refer-
ences therein). Cells were sequentially treated with fluorescent 
probes (XVA-FITC or BIRT-FITC; Figure 6, first arrow), vehicle 
(dimethyl sulfoxide [DMSO], green lines), or PKH26 (red and blue 
lines) to induce quenching of the signal (Figure 6, second arrow) 
and activated with TPA/TG mixture (red and green lines) or control 
kinetics, for which acceptor densities are the lowest. We evaluated 
the slopes of the lines starting at the point of lipid acceptor addi-
tion (dashed lines in Figure 3). We normalized quenching curves, 
assuming that the initial fluorescence (before PKH26 addition) is 
equal to 1 and maximal quenching is equal to 0. Because the addi-
tion of the acceptor creates a 5- to 10-s gap in the time course and 
the majority of XVA-FITC quenching occurs during this time, the 
rate of XVA-FITC quenching should be considered a lower limit 
(the actual rate can be faster). No such problem exists for BIRT-FITC 
because the quenching is slow (Figure 3B). Next we plotted the 
slopes and normalized them to the slope of XVA-FITC (Figure 5B). 
These data are compared with the theoretical data presented in 
Figure 5A (numbers in red).
Rapid quenching of XVA-FITC as compared with the BIRT-based 
probe can be interpreted as indicating that, at rest, the XVA-143 
binding site is closer to the membrane. According to the theory, the 
initial slope of the quenching curve changes about one order of 
magnitude (from 1.00 to 0.09) when the distance of closest ap-
proach changes from 0R0 to 1.3R0 (Figure 5A). With this result, we 
can use the experimental slope difference to estimate the relative 
distance between the two binding sites. Because the absolute posi-
tion of the XVA-143 site relative to the membrane is unknown, sev-
eral assumptions can be made. If the XVA-FITC resides close to the 
membrane (rc/R0 = 0), a relative slope of ∼0.3 corresponds to a dis-
tance of ∼rc/R0 = 1 (Figure 5A). If XVA-FITC is positioned farther 
away from the membrane (rc/R0 = 0.7), the relative slope value of 
∼0.3 results in rc/R0 = 1.3, and Δ(rc/R0) = (1.3 − 0.7)R0 = 0.6R0. Thus, 
depending on the initial position of XVA-FITC binding site, the ob-
FIGURE 3: Binding and quenching kinetics for two LFA-1–specific probes. The experiment 
involves sequential additions of fluorescent donor probes (XVA-FITC, 100 nM [A, C], or BIRT-
FITC, 60 nM [B, D]) and the PKH 26 acceptor probe, 0.5 μM (A, B), 0.25–2 μM (C), and 0.25–4 μM 
(D). Control samples were treated with vehicle (DMSO). A representative experiment of three 
independent experiments is shown. Each experimental point represents an average of several 
hundred events acquired with 1-s time resolution. Initial parts of the quenching curves were 
fitted to a single-exponential decay equation. Decay constants (k) are indicated on C and D.
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(DMSO, no activation, blue line; Figure 6, third arrow). Cell activa-
tion using TPA/TG resulted in the unquenching of the probe sig-
nal to a level equivalent to the unquenched controls samples, for 
which no lipid acceptor was added (green lines). This complete 
unquenching of the signal suggests that the donor probes moved 
away from the acceptor, and the distance of closest approach is 
much larger than the Förster distance (rc >> R0). This result is 
expected for fully extended LFA-1, for which the estimated mole-
cular length is >200 Å (Figure 2). It also suggests that the majority 
of integrins, occupied by the probe, responded to activation stim-
uli. Because each experimental point represents an average of 
500–1000 events acquired by a flow cytometer every second, the 
majority of cells in the population also responded to the treat-
ment. Thus physiologically relevant inside-out activation results in 
significant extension of LFA-1.
Phorbol ester alone is not sufficient to induce full donor 
signal unquenching, and thapsigargin, an intracellular 
calcium releaser, is necessary to promote full LFA-1 
extension
Phorbol esters activate conventional protein kinase Cs (PKCs) by 
mimicking diacylglycerol in the absence of Ca2+ signaling. To de-
termine whether TPA alone produces a conformational unbending 
of LFA-1, we performed the FRET assay (Figure 7). Cells were 
treated with XVA-FITC or BIRT-FITC probes. Next the probe fluo-
rescence was quenched with PKH 26. Cells were then activated by 
TPA/TG mixture or TPA alone (Figure 7, blue and green lines). 
DMSO was used as a negative control (Figure 7, black line). Thapsi-
gargin, an inhibitor of sarcoendoplasmic reticulum Ca2+−ATPases 
that elevates cytoplasmic calcium concentration by depleting in-
tracellular stores, was also later added to TPA-treated cells (Figure 
7, red line). Cells treated with TPA alone showed a small decrease 
in donor fluorescence right after compound addition, followed 
by slow signal unquenching (Figure 7, green lines). However, 
by the end of the experiment, it did not reach the level of the 
fully unquenched signal induced by the TPA/TG mixture. Addition 
of thapsigargin resulted in a rapid unquenching of the FRET do-
nor (Figure 7, red line) that at the end of the experiment went to 
the level equivalent to the TPA/TG-activated cells. This result sug-
gests that the distance of closest approach between the probe 
binding sites and the membrane (rc in Figure 2) was much larger 
than the Förster distance (rc >> R0) in both cases. Thus cytosolic 
calcium elevation is necessary for the full extension of LFA-1 
integrin.
No visible segregation or clustering of LFA-1 molecules can 
be detected after cell activation
Based on current knowledge about LFA-1 activation and confor-
mational changes, it is tempting to attribute rapid unquenching of 
the donor fluorescence to the increase in the distance of closest 
FIGURE 4: Effect of unlabeled allosteric antagonists (A, B) and cell 
metabolic activity (C) on real-time quenching of FRET donors. Cell 
were sequentially treated with 60 nM BIRT-FITC (A), 100 nM XVA-
FITC, the PKH 26 acceptor (0.5 μM), and 1 μM unlabeled XVA-143 (A), 
or BIRT 377 (B). Controls were treated with vehicle (DMSO). The order 
of compound addition is indicated by arrows. (C) Before the 
experiment, cells were preincubated with a mixture of metabolic 
inhibitors (0.2% sodium azide and 50 nM 2-deoxy-d-glucose) for 5 min 
at 37°C. Control sample was pretreated with vehicle (DMSO). Next 
fluorescent donor (XVA-FITC, 100 nM) and acceptor (PKH 26, 0.5 μM) 
were sequentially added to the cell mixture. Each experimental point 
represents an average of several hundred events acquired with 1-s 
time resolution. Each line represents a mean of two runs (n = 2) 
calculated on a point-by-point basis. One representative experiment 
of three experiments is shown.
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the additional fluorescence. Next we ex-
amined the ability of inside-out activation 
to affect the distribution of LFA-1 mole-
cules (Supplemental Figure S3, C and D). 
After treatment with the TPA/TG mixture, 
no observable changes in the lateral distri-
bution of the fluorescence signal within 
3–6 min were detected. Thus, on the time 
scale corresponding to the real-time FRET 
experiments, no visible changes in redistri-
bution or surface expression of LFA-1 was 
detected. However, because of the limited 
resolution of the microscope optical sys-
tem, these experiments cannot rule out the 
existence, rapid de novo formation, or dis-
sociation of nanometer-size domains, lipid 
rafts, or protein clusters. Rapid segregation 
of the donor probe bound to the receptor 
protein from the acceptor probe in the 
membrane for a distance comparable to 
the Förster distance (R0 ≈ rc) would result in 
modification of the energy transfer.
DISCUSSION
FRET-based approaches are essential 
for understanding protein molecular 
dynamics
Obtaining the crystal structure of a protein 
usually initiates a large number of studies 
aimed at understanding the “working cycle” 
of a specific molecular nanomachine. For in-
tegrins, one of the major classes of adhesion 
molecules, the finding of a “severely bent” 
extracellular portion (Xiong et al., 2001) re-
sulted in the hypothesis that the bent confor-
mation represents the resting inactive integ-
rin state and the extended state corresponds 
to the active integrin (Beglova et al., 2002). 
This hypothesis relied on the exposure of 
conformationally sensitive mAb epitopes 
that are described for a large number of inte-
grins. Alone, they can induce (or stabilize) 
specific integrin conformations (Byron et al., 
2009). Additional approaches, including electron microscopy of puri-
fied mutated integrins, together with molecular dynamics simulations 
revealed a complex picture of multiple conformational states that can 
be directly translated into the different cell adhesive behavior (Shi-
maoka et al., 2003b; Nishida et al., 2006; Askari et al., 2009; Camp-
bell and Humphries, 2011). However, according to Askari et al. (2009), 
multiple key questions remain, including that of the relationship of 
integrin extension and activation.
To understand the role of VLA-4 conformational regulation in cell 
adhesion, we developed an alternative approach. It relies on fluo-
rescent ligand–mimicking probes that can be used to study modula-
tion of the ligand binding affinity, as well as integrin extension, using 
a FRET-based approach (Chigaev et al., 2001, 2003, 2007; Chigaev 
and Sklar, 2012b). FRET is established between a small, integrin-
specific ligand donor bound to the integrin head group at saturating 
concentration, and fluorescent lipid acceptors are incorporated into 
the cell membrane. These studies can be conducted on naturally 
expressed, unmodified integrins in primary cells or cell lines under 
the control of inside-out signaling pathways. The use of real-time 
approach between donor and acceptor probes solely due to the 
straightening of the integrin “legs” from a bent to an extended 
conformation. However, the FRET models used here do not, on 
their own, discriminate between lateral and vertical separation 
distances between the donor and acceptor probes (Chigaev et al., 
2003). It is possible that lateral segregation or clustering of the 
molecules can contribute to the changes in FRET. To address this 
issue, we tested whether cell treatment affects the gross surface 
distribution of LFA-1 molecules on the time scale relevant to our 
experiments. Cells treated in a manner analogous to the flow cy-
tometry experiments were fixed, and LFA-1 molecules were 
stained using primary labeled monoclonal antibodies (mAbs; Sup-
plemental Figure S3).
We found that the surface distribution of the LFA-1 integrin 
on TALL-104 cells was moderately diffuse. Minor uneven surface 
distribution of the fluorescence often described as ‘‘integrin clus-
ters’’ (Supplementary Figure 3, blue arrows) corresponds to the 
sites of microvilli (Chigaev et al., 2003), as the presence of an 
additional quantity of membrane in these sites may account for 
FIGURE 5: Energy transfer as a function of donor distance of closest approach expressed in 
terms of R0 according to the calculations of Wolber and Hudson (Eq. 4) and the estimated 
relative difference between the distance of closest approach (rc) for BIRT-FITC and XVA-FITC 
probes bound to LFA-1. (A) Theoretical quenching curves calculated according to Eq. 4 and 
initial rates of acceptor quenching. The absolute initial quenching rates were evaluated as the 
slopes of the dashed lines for each distance of closest approach. Next slopes were normalized, 
assuming the slope of the line corresponding to 0R0 or 0.7R0 distance is equal to 1 (rc/R0 = 0 or 
0.7, slope = 1) and summarized in Table 1. (B) Experimentally determined initial quenching rates 
as for the experiments shown in Figure 3. Kinetic curves were normalized assuming that the 
initial signal before the addition of the acceptor is equal to 1 and maximal donor quenching at 
its peak is equal to 0. Next slopes of the initial quenching curves were calculated (see Figure 3, 
slope) and normalized to the slope of the XVA-FITC curve. Average values of three experimental 
determinations. Normalized values ± SEM are shown next to the bars. Asterisk, significantly 
different (p < 0.05) as estimated by unpaired t test using Prism software. (C) Proposed model of 
the LFA-1 resting conformation. Slower quenching rates for the BIRT-FITC probe can be 
interpreted as if the distance of the closest approach for this probe (rc2) is ∼(0.6–1.0)R0 larger 
than the distance for XVA-FITC probe (rc1), and thus the BIRT 377 binding site is positioned 
farther away from the membrane. Red arrow and a question mark indicate the proposed 
position of the α I domain, where the BIRT 377 site is located.
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VLA-4, for which the association rate (kon) for 
the ligand-mimicking probe is close to the 
diffusion-limited rate and largely indepen-
dent of the integrin activation state (Chigaev 
et al., 2011b; Chigaev and Sklar, 2012a). This 
makes it impossible to perform a FRET-based 
extension assay in a manner analogous to 
VLA-4. To overcome this obstacle, we used 
fluorescent donors based on LFA-1 allosteric 
antagonists that bind to LFA-1 integrin with-
out activation (at rest). Because binding sites 
for these compounds are known and sepa-
rated by distance similar to the Förster dis-
tance (R0) for our donor/acceptor pair, the 
use of the two probes creates a molecular 
ruler that can be used to obtain positional 
information.
Position of allosteric antagonist-based 
probes at rest
A majority of current LFA-1 conformational 
models agree on the overall structure of the 
resting (inactive) conformation of LFA-1. It is 
depicted as a bent structure, similar to the crystal structure of αXβ2 
integrin (Xie et al., 2010), with the α I domain (von Willebrand factor-
A, αA domain) pointing downward, or at least parallel to the mem-
brane. To our surprise, the real-time quenching kinetics for the two 
probes was dramatically different and consistent with an estimate 
that BIRT-FITC probe was localized ∼(0.6–1)R0 from the XVA-FITC 
probe and farther from the lipid donor incorporated in the cell mem-
brane. To our knowledge, no such conformations were proposed 
before (Figure 5C). However, it is also possible that this conforma-
tion is a result of the LFA-1 ligation by BIRT 377 and thus a stabiliza-
tion of an inactive (Woska et al., 2001) and somewhat artificial con-
formation. The quenching of the XVA-FITC probe was comparable 
to the quenching of LDV-FITC probe previ-
ously used for VLA-4 experiments. Both 
probes occupy a homologous binding site 
that is located between the α-subunit β-
propeller and β subunit I–like domain (β A 
domain; Shimaoka and Springer, 2003). 
Thus, for both VLA-4 and LFA-1 at rest, this 
site is located close to the membrane-incor-
porated lipid acceptors.
Distance of closest approach: vertical 
versus lateral separation
FRET is a distance-dependent interaction 
between the electronic excited states of two 
fluorophores for which excitation is trans-
ferred from an excited donor to an acceptor. 
Thus the FRET-based approach used here 
does not discriminate between lateral and 
vertical separation distances between the 
donor and acceptor probes. Moreover, our 
microscopy data cannot rule out the forma-
tion of nanoscopic clusters of integrins or 
other membrane molecules that could po-
tentially form a “sheath” around integrin re-
ceptors “shielding” donor probes from ac-
ceptor quenching. One can also hypothesize 
that lipid acceptors can rapidly partition into 
flow cytometry in which live, unfixed cells maintained at 37°C are 
resuspended and continuously mixed in a physiologically relevant 
solution allows for the addition of various natural or artificial ligands 
to explore interactions of multiple signaling pathways (Chigaev 
et al., 2008, 2011a). Thus this approach is very useful for real-time 
studies of VLA-4 conformation. However, until recently, we were un-
able to apply this approach to studies of LFA-1.
LFA-1 ligand binding poses additional challenges
Our recent findings indicate that in the absence of inside-out activa-
tion, the binding of a small ligand-mimicking probe based on a direct 
(competitive) antagonist to LFA-1 is extremely slow, as opposed to 
FIGURE 6: Energy transfer on TALL-104 cells between XVA-FITC (A) and BIRT-FITC (B) donor 
probes and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine (PKH 26) acceptor probe. 
Real-time FRET experiments are as described in Figure 3, except that cells were treated with 
(A) XVA-143 donor (100 nM) or (B) BIRT-FITC (60 nM), PKH 26 acceptor (0.5 μM), and a mixture 
of TPA (500 nM) with TG (10 μM), red line. Control samples were treated with the same 
concentrations of donor probes, acceptor or vehicle, or a mixture of TPA/TG or vehicle. Each 
line represents the mean of two determinations (n = 2) calculated on a point-by-point basis. 
SEM is shown for every 10-s time point.
FIGURE 7: Effect of thapsigargin on energy transfer between donor probes and PKH 26 
acceptor probe. Cells were treated with 100 nM XVA-FITC (A) or BIRT-FITC (B), PKH 26 acceptor 
(0.5 μM), or vehicle (DMSO). Next phorbol ester alone (TPA, green line), TPA/TG mixture (blue 
line), or vehicle (black line) was added. In addition a sample treated with TPA alone was treated 
with TG (red line). Note the rapid signal unquenching after the addition of TG (red line), which 
reaches the level of the TPA/TG mixture (blue line), and the unquenched control (gray line, B). 
Compound concentrations were analogous to Figure 6. One representative experiment of four 
experiments is shown. Each line represents the mean of two determinations (n = 2) calculated on 
a point-by-point basis. SEM is shown for every 25-s time point.
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the membrane and the ligand-binding site 
of the α I domain ranges from 8 to 74 Å for 
the resting state (bent conformation). On 
activation, it increases to 230–250 Å (ex-
tended conformation; Nishida et al., 2006). 
Our experimental data are in a good agree-
ment with these distance estimates. At rest, 
fluorescent probes bound to the LFA-1 head 
group and the α I domain can be both suc-
cessfully quenched, as if the distance of 
closest approach was comparable to the 
Förster distance (R0 ≈ rc, Table 1; R0 = 50–60 
Å). The inside-out activation resulted in the 
complete unquenching of both donor 
probes (Figure 6). This suggests that probes 
were moved out of the FRET range (rc >> 
R0), which for our pair of fluorophores is 
>100 Å. Thus, to the best of our knowledge, 
LFA-1 integrin extension upon activation 
represents the most plausible explanation 
for the observed fluorescence intensity 
changes (Figure 8).
Allosteric antagonists and molecular 
extension
One of the features assigned to the XVA-
143 allosteric antagonist is the ability to in-
duce the extended conformation of β2-
integrins without any additional signaling 
requirements. This notion was based on two 
types of observations: enhancement of cell 
rolling and adhesion, and exposure of 
KIM127 mAb epitope mapped to the resi-
dues within the I-EGF-2 domain (a “genu”; 
Figure 2) of the β2 subunit (Salas et al., 2004, 
2006). It is envisioned that the extension of 
the integrin genu leads to the epitope exposure (Beglova et al., 
2002). This idea was also somewhat supported by EM of purified 
αXβ2-integrins, for which, in the presence of XVA-143, only ∼40% of 
clasped integrin constructs adopted an open conformation and 60% 
remained bent. The fact that the unclasped constructs show greater 
sensitivity to XVA-143 is not crucial since the unclasping by itself was 
sufficient to induce the extended conformation in ∼75% of cases 
(Figure 2, C and D, in Nishida et al., 2006).
In our experiments, if the addition of XVA-143 would have been 
sufficient to shift the dynamic state equilibrium and induce the 
extended LFA-1 state, we would expect to have detected a time-
dependent unquenching of the fluorescent signal. We did in fact 
observe a slow increase in the donor fluorescence when the 
XVA-FITC probe was used (Figures 3A, 6A, and 7A). Previously this 
a lipid raft or a nonraft microdomain that is laterally separated from 
donor molecules. However, several experimental results argue that 
the distance change represents the vertical rather than the horizon-
tal separation between donors and acceptors.
The use of two donor probes bound to two different binding 
sites on the same receptor molecule creates a unique situation in 
which the quenching kinetics induced by the incorporation of lipid 
acceptors can be directly compared. Our observation that the initial 
rates of the donor probe quenching are dramatically different from 
the very beginning of the experiment suggests that the probe posi-
tioning rather than lateral receptor segregation or lipid acceptor in-
corporation is important. Moreover, a large excess (10-fold) of the 
other unlabeled probe introduced into the experimental medium 
together with each fluorescent donor probe had no effect on the 
overall quenching kinetics (Figure 4). These experiments suggest 
that the binding of the probe to the extracellular part of LFA-1 has 
no significant effect on LFA-1 conformation or on lipid membrane 
domain structure and composition to the point that it will interfere 
with the incorporation of the lipid molecules into the membrane. 
Therefore the difference in the quenching kinetics at rest is more 
likely attributed to the different probe positioning within the LFA-1 
receptor (Figure 8, A and B).
Integrin extension upon activation was first described as a result 
of the analysis of atomic models and epitope exposure and the 
analysis of electron microscopy (EM) of purified integrins (Takagi 
et al., 2002). Based on EM models, the estimated distance between 
FIGURE 8: Schematic depiction of energy transfer between donor probes (green) and PKH 26 
acceptor probe (red) for different conformational states of LFA-1. Insets schematically show 
quenching and unquenching kinetics. At rest, the XVA-FITC probe bound to the LFA-1 head 
group (A) requires a lower density of acceptors and in real-time experiments show rapid 
quenching kinetics because the probe binding site is located closer to the membrane. BIRT-FITC 
probe bound to α I domain (B) is located farther away from the membrane. Therefore a higher 
acceptor density is required for quenching. In real time, this is translated into slower quenching 
kinetics (compare A and B insets). After LFA-1 extension induced by inside-out activation (arrows 
on C and D insets), we observed complete unquenching of the probe fluorescence. This 
suggests that the integrin “leg” extension is sufficient to move both probes out of the FRET 
range (rc >> R0).
κ2





Values were calculated as described in Estimation of the Förster distance.
TABLE 1: Calculated values of R0 for XVA-FITC, BIRT-FITC, and 
PKH26 pairs for two different dipole–dipole orientation factors, κ2.
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binding) can modify LFA-1 conformation and creates various activa-
tion states (Hogg et al., 2011). In previous studies, for a different 
leukocyte integrin (VLA-4), we reported that TPA alone was capable 
of inducing the high-affinity conformation without molecular exten-
sion detected in a FRET-based assay (Chigaev et al., 2007). The data 
supported the existence of multiple conformational states indepen-
dently regulated by both inside-out signaling and ligand binding 
(Chigaev et al., 2009). Data presented in the present report suggest 
that LFA-1 extension is regulated in a manner that is similar to VLA-
4. The elevation of cytoplasmic calcium is essential for the molecular 
extension (compare Figure 3C in Chigaev et al., 2007, and Figure 7 
in the present article). However, for LFA-1, which possesses an ad-
ditional α I domain, conformational regulation is expected to be 
even more complex. We propose that this complexity, which origi-
nates from an evolutionary divergence among ancient and more 
modern leukocyte integrins, can be directly linked to different func-
tional roles of LFA-1– and VLA-4–dependent adhesive interactions 
(Chigaev and Sklar, 2012a).
In addition, two probes based on LFA-1 allosteric antagonists 
showed somewhat different responses to phorbol TPA and TG treat-
ment. TPA alone induces slight unquenching of XVA-FITC signal, 
and no significant signal change was detected for the case of 
BIRT377-FITC (Figure 7). This result can possibly indicate some de-
gree of extension of LFA-1 after treatment with TPA. According to 
our model, the probe that initially located closer to the membrane 
and quenched at lower acceptor density would exhibit a higher sen-
sitivity to small changes in the position of the integrin head group 
(Figure 8). Therefore XVA-FITC probe fluorescence will be more 
sensitive to the small changes in the distance of the closest 
approach (rc). Alternatively, allosteric antagonists bound to two 
different sites within the LFA-1 molecule can modify dynamic con-
formational equilibrium and favor different conformations of the 
receptor. Therefore, since BIRT 377 treatment has been reported to 
stabilize a certain specific LFA-1 conformation (Woska et al., 2001; 
Green et al., 2006), it is possible that LFA-1 extension in the pres-
ence of BIRT 377 is somewhat constrained.
MATERIALS AND METHODS
Cells
The human acute lymphoblastic leukemia cell line TALL-104 was 
purchased from the American Type Culture Collection (Rockville, 
MD; CRL-11386). Cells were grown at 37°C in a humidified atmo-
sphere of 10% CO2 and 90% air in Iscove’s modified Dulbecco’s 
medium (supplemented with 100 U/ml recombinant human interleu-
kin-2, 2 mM l-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, 
and 20% heat-inactivated fetal bovine serum; Life Technologies, 
Carlsbad, CA). Cells were counted using the Coulter Multisizer/Z2 
analyzer (Beckman Coulter, Brea, CA). For experiments, cells were 
suspended in Iscove’s modified Dulbecco’s medium at 1 × 106 cells/
ml at 37°C and used immediately. All other reagents were from 
Sigma-Aldrich (St. Louis, MO).
Probes for FRET
The LFA-1–specific ligands BIRT 377 (Woska et al., 2001), XVA-143 
(Welzenbach et al., 2002) and fluorescent (fluorescein-conjugated) 
analogues BIRT-FITC and -FITC (Figure 1) were synthesized by Wei 
Wang at the Department of Chemistry and Chemical Biology, 
University of New Mexico. Fluorescent dye PKH26 (Figure 1) was 
purchased from Sigma-Aldrich (PKH26GL). Fluorescein analogues 
were used as FRET donors and PKH26 as acceptor. For experi-
ments, stock solutions were prepared in DMSO at concentrations 
drift was attributed to the acceptor lipid flip-flop between the outer 
and inner leaflets, as well as acceptor internalization (Chigaev et al., 
2003). In this report, the use of PKH26 dye with two C18 chains pro-
vided better signal stability. However, in the absence of the inside-
out activation, the quenched XVA-FITC donor signal never reached 
the unquenched control, for which no lipid was acceptor added.
We also attempted to see whether the addition of the unlabeled 
allosteric antagonist to the cells labeled with the fluorescent probe 
based on the other antagonist resulted in a signal change that can 
be interpreted as molecular extension. No statistically significant 
change was detected (Figure 4, A and B). Thus no extension in-
duced by XVA-143 was detected using a FRET-based approach.
Extension after cell activation
Activation of the inside-out signaling pathways using a combination of 
phorbol ester and thapsigargin induced rapid unquenching of donor 
fluorescence. This combination of drugs produces activation of the 
TALL-104 cell line, which is analogous to the TCR/CD3 T-cell–specific 
signaling pathway (Lyubchenko et al., 2001). The fact that donor fluo-
rescence reaches the level of the unquenched positive control can be 
interpreted as an extension of the molecule, and the distance of the 
closest approach between the cell membrane and the probe binding 
site is severalfold larger than the Förster distance for the two fluoro-
phores. Because the length of the LFA-1 extracellular domain is 
>200 Å (Figure 2), this interpretation appears to be realistic.
It is worth noting that for VLA-4 inside-out activation, the donor 
fluorescence never reached the level of the unquenched control, 
similar to LFA-1. At best, after activation, the signal increased up to 
40–50% of the initial value. This was interpreted as if the change in 
distance of closest approach was close to R0 (Chigaev et al., 2003, 
2007). An alternative interpretation is that only a small fraction of 
integrins on the cell surface, or only a fraction of cells, responded to 
the activating signal. Because acquisition rates in kinetics experi-
ments can reach several hundreds of events per second, with aver-
aging of the signal, it is impossible to distinguish between these 
possibilities (Chigaev et al., 2003, 2007).
The other important feature of integrin extension is the calcium 
dependence. Previously we found that treatment of cells with phor-
bol ester alone was insufficient to induce an extension of VLA-4, as 
detected using FRET. Addition of the Ca2+ ionophore resulted in the 
rapid unquenching of the donor fluorescence (Chigaev et al., 2007). 
We tested whether LFA-1 extension exhibited a similar feature. We 
found that unquenching of both LFA-1–specific probes was in fact 
dependent on the release Ca2+ from intracellular stores (Figure 7). 
The data were strikingly similar despite all the differences between 
the two studies: different cell lines, integrins, donor and acceptor 
probes, and Ca2+-elevating compounds were used (compare Figure 
3C in Chigaev et al., 2007, and Figure 7 in the present article). Thus 
LFA-1 allosteric antagonist–based fluorescent probes can be used 
for real-time studies of integrin extension. This approach will pro-
vide invaluable information concerning conformational regulation 
of LFA-1 on live cells and help to answer a number of the key re-
maining questions that describe the structure–function relationships 
of LFA-1 (Askari et al., 2009).
Multiple states and integrin regulation
Current models of LFA-1 conformational regulation include multiple 
conformational states. In the classical model, three distinct confor-
mations classified according to ligand binding affinity and extension 
have been described: low-affinity, bent; intermediate-affinity, 
extended; and high-affinity, extended states. Introduction of a lat-
eral shear force or “opposing” force (or counter force from ICAM-1 
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FD(λ) is dimensionless intensity, representing a corrected emission 
spectrum of the donor normalized to unity at the band maximum, 
εA(λ) is an extinction coefficient expressed in units of M−1 cm−1, and 
λ is wavelength in centimeters. The overall units of J are cm3 M−1. 
The calculated value of J for the fluorescein–PKH26 pair is 2.8 × 
10−13 cm3 M−1. This is slightly than reported for a fluorescein–rhod-
amine pair (Chigaev et al., 2003) due to the difference in acceptor 
absorption spectra. Calculated values of R0 for XVA-FITC, BIRT-FITC. 
and PKH26 pairs are given in Table 1. Thus, for our experiments, R0 
is in the range 50–55 Å.
Energy transfer in two dimensions. Energy transfer data were 
analyzed by expressions that describe energy transfer between 
random distributions of donors and acceptors on lipid membrane 
surfaces (Fung and Stryer, 1978; Wolber and Hudson, 1979; Dewey 
and Hammes, 1980; Doody et al., 1983). We used an approach 
(Wolber and Hudson, 1979) that involves the calculation of the 
distance of closest approach (rc) between randomly distributed 
donors and acceptors on an infinite plane and is described by a 
simple series approximation as
Q
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where c = acceptors/R02, acceptor density (ac/R02). 
The values of A1, k1, A2, and k2 were taken from Table 1 in 
Wolber and Hudson (1979) and correspond to the exact solution 
to the series approximation for different values of rc expressed 
as a function of R0. It is important to note that the values of k2 for 
rc/R0 = 1.1 and 1.3 in the original reference (Wolber and Hudson, 
1979) have been corrected from 0.4654 and 0.5633 to 0.04654 
and 0.005633, respectively (see Table 15.2 in Lakowicz, 2010). This 
approach is valid for 0 < c < 0.5 and when the distance of closest 
approach is <1.3R0. Outside of this range, FRET is significantly 
overestimated. The curves generated using this approach were 
used to estimate the relative difference between the distance of 
closest approach (rc) between BIRT-FITC and XVA-FITC probes 
bound to LFA-1.
FRET experimental design. Addition of the fluorescent cationic 
amphiphilic lipids used as FRET acceptors to live cells results in 
rapid partitioning of the molecules into the cell membrane, which 
can be monitored in real time using a flow cytometer (Chigaev et al., 
2003; Buranda et al., 2010). This time-dependent increase in FRET 
acceptor density results in the quenching of membrane-associated 
FRET donors of different origin. For integrin ligands bound to the 
integrin head group, rapid conformational extension of the molecule 
results in donor unquenching that was interpreted as the change in 
the distance of closest approach (rc) between receptor-bound 
ligands and the cell membrane (Chigaev et al., 2003, 2007; Larson 
et al., 2005). Because of the inability of the LFA-1 receptor to bind a 
small ligand-mimicking fluorescent probe in the absence of integrin 
activation (Chigaev et al., 2011b; Chigaev and Sklar, 2012a), it 
was impossible to use it as a FRET donor as previously done for 
VLA-4 integrin (Chigaev and Sklar, 2012b). Therefore we created 
fluorescent probes based on LFA-1–specific allosteric antagonists 
that are known to bind to LFA-1 without activation (BIRT 377 and 
XVA-143).
Real-time FRET experiments were performed as described 
previously(Chigaev and Sklar, 2012b). Flow cytometric data were 
∼1000-fold higher than the final concentration. Usually, 1 μl of stock 
solution was added to 1 ml of cell suspension, yielding a final 0.1% 
DMSO concentration. Control samples were treated with an equal 
amount of pure DMSO (vehicle).
The binding of BIRT-FITC was first studied in our laboratory in 
2005 (Larson et al., 2005). The dissociation constant (Kd) and dissocia-
tion rate (koff) were ∼70–100 nM, and ∼0.04–0.1 s−1, respectively. This 
places the calculated association rate constant (kon) in the range 
∼(0.4–1.4) × 106 M−1 s−1, which approaches the diffusion-limited rate 
for ligands of similar size (Chigaev et al., 2011b). Moreover, binding of 
the probe did not require cell activation, and ligand-binding affinity 
was essentially independent of cell activation (Larson et al., 2005).
XVA-143, also referenced as Roche compound #5, inhibited 
binding of β2-integrin to its ligands with an IC50 value of 60 ± 10 nM, 
blocked LFA-1–mediated cell adhesion to ICAM-1 with IC50 > 10 nM, 
and inhibited the LFA-1/ICAM-1–dependent mouse mixed leuko-
cyte reaction with IC50 ≈ 20–40 nM (see Figure 2 in Shimaoka et al., 
2003a). Our data (Supplemental Figure S2) suggest that the Kd for 
unlabeled XVA-143 binding is ∼80–90 nM, and the koff for the FITC-
labeled XVA-FITC probe is ∼0.04 ± 0.003 s−1. Thus the ligand-bind-
ing affinity of XVA-143 is similar to the affinity of BIRT 377.
Fluorescence resonance energy transfer
General considerations. FRET is a distance-dependent interaction 
between the electronic excited states of two fluorophores in which 
excitation is transferred from an excited donor (D*) molecule to an 
acceptor (A) molecule without emission of a photon. The 
characteristic distance at which the donor fluorescence and FRET 
are equally probable is defined as R0, the Förster distance. On a 
surface, the efficiency of FRET is determined from the reduction in 
the emission quantum yield of the donor according to the following 
equation, where QD refers to the emission yield of the donor in the 
absence of acceptors, and QDA refers to the donor emission yield in 
the presence of acceptors expressed in terms of acceptors per unit 







Determination of the relative fluorescence quantum 
yield. Conjugation (coupling) of fluorophores typically decreases 
the fluorescence quantum yield. To determine the relative quantum 
yield of the LFA-1–specific fluorescent probes, absorption- 
matched samples of carboxyfluorescein and the fluorescent LFA-1 
probes (at 490 nm) were used to acquire emission spectra 
(Supplemental Figure S1). The relative quantum yield for XVA-FITC 
was determined as ∼0.70 and for BIRT-FITC was ∼0.30. These 
coefficients were used to calculate R0 values.
Estimation of the Förster distance. R0 was calculated according to
R JQ n( / ) (9.79 10 ) (in Å)0 D 2 4 1/6 3κ= ×  (2)
where J is the donor–acceptor spectral overlap, QD is the quantum 
yield of the donor in the absence of acceptor, κ2 is the dipole–dipole 
orientation factor (usually taken as 2/3), and n is the refractive index 
(1.333) of the medium (Lakowicz, 2010). For randomized static ori-
entations of donors and acceptors, κ2 = 0.476. In the case of LFA-
1–specific probes immobilized by LFA-1 and PKH26 embedded in 
the cell membrane, a combination of dynamic and static factors is 
likely in place.
J is the overlap integral that expresses the degree of overlap 
between the donor emission and acceptor absorption,
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considered as two rigid systems. The resulting models were refined 
to reduce the steric clashes of the side chains without changing the 
receptor backbone using the Biopolymer module from the Sybyl 
software suite (Sybyl 7.3; Tripos International).
Confocal microscopy
TALL-104 cells suspended in complete Iscove’s modified Dulbecco’s 
medium at 1 × 106 cells/ml were treated with appropriate com-
pounds (TPA, TG) in a manner analogous to flow cytometry experi-
ments described in FRET experimental design. Next cell aliquots 
were removed and immediately fixed in ice-cold 2% paraformalde-
hyde before cell activation and 3 and 6 min after the addition of 
TPA/TG mixture and stored at 4°C overnight. The next day, cells 
were washed with ice-cold PBS and stained with primary labeled 
(phycoerythrin) fluorescent mAbs (mouse anti-human CD11a/LFA-
1α, clone HI111 [PE] from BD Biosciences, San Jose, CA) for 30–40 
min on ice according to manufacturer’s instructions. Samples were 
mounted using SlowFade Gold Antifade Mountant with 4′,6-diamid-
ino-2-phenylindole (Life Technologies). Fluorescence microscopy 
was performed with a confocal microscope (Zeiss 510 Laser Scan-
ning Microscope 510-META) using an oil immersion objective lens at 
the University of New Mexico Fluorescence Microscopy and Cell Im-
aging Shared Resource facility. Images were obtained and processed 
using ZEN 2009 image analysis software (Carl Zeiss MicroImaging).
acquired continuously using a FACScan (Becton Dickinson) flow 
cytometer at constant temperature (37°C), and the samples were 
stirred continuously at 300 rpm with a 5 × 2 mm magnetic stir bar 
(Bel-Art Products). Cells suspended in Iscove’s modified Dulbecco’s 
medium at 1 × 106 cells/ml were transferred into a FACScan tube, 
and samples were analyzed for 30–120 s to establish a baseline for 
unstained cells marked as “cell autofluorescence.” Next the fluores-
cent probes that served as FRET donors (BIRT- or XVA-FITC) were 
added, and acquisition was reestablished, creating a 5- to 10-s gap 
in the time course, which can be observed in the figures. A few min-
utes later, after donor probe equilibration, the FRET acceptor 
(PKH26) was added, and donor quenching was followed continu-
ously up to 1024 s. For real-time signaling experiments, to elicit 
signaling responses, cells were treated with appropriate compounds 
(TPA, TG, and others). In several experiments, cells were treated 
sequentially with two or more compounds. Acquisition was reestab-
lished, and data were acquired continuously up to 1024 s. Kinetic 
curves were analyzed using the FCSQuery software developed by 
Bruce S. Edwards (University of New Mexico).
Estimation of total LFA-1 (CD11a/LFA-1α) expression
The expression of CD11a was measured with primary labeled (phy-
coerythrin) fluorescent mAbs (mouse anti-human CD11a/LFA-1α, 
clone HI111 [PE] from BD Biosciences) and quantified by compari-
son with a standard curve generated using Quantum Simply Cellular 
anti-mouse immunoglobulin G beads (Bangs Laboratories) stained 
in parallel with the same mAb. This produces an estimate of the to-
tal mAb binding sites/cell. Typically, we find 1,000,000–1,200,000 
LFA-1 sites/TALL-104 cell. This high CD11a expression justified our 
choice of the cell line and produced an excellent signal-to-back-
ground ratio. Because of the high expression of the CD11a subunit, 
our data primarily describe the CD11a/CD18 (LFA-1) integrin.
Statistical analysis
Curve fits and statistics were performed using Prism, version 4.00 for 
Windows (GraphPad Software, San Diego, CA). Each experiment 
was repeated at least three times. The experimental curves repre-
sent the mean of two or more independent runs. SEM was calcu-
lated using Prism.
LFA-1 model
The 3D structure of LFA-1 (αLβ2) integrin in the bent, closed confor-
mation was obtained by assembling the x-ray structure of the β2 
subunit with the homology model of the αL subunit built based on 
the x-ray structure of the αX subunit (Xie et al., 2010). The sequence 
of the human αL integrin was extracted from the Uniprot database 
(Boutet et al., 2007) in Fasta format and was automatically aligned 
using the T-coffee server (Poirot et al., 2003) with the sequence of 
the human αX integrin obtained from the RSCB Protein Data Bank 
(accession code 3K6S; Xie et al., 2010). The alignment of the amino 
acid sequences generated by the T-coffee server was manually re-
fined using as a guide the 3D structure of the template in order to 
avoid deletions or insertions in the transmembrane domains and 
preserve the highly conserved amino acid motifs. When necessary, 
the deletions and insertions were merged into a single piece per 
loop and placed in the most adequate point in accordance with the 
template structure. The homology modeling package Modeller ver-
sion 9v7 (Sali and Blundell, 1993; Eswar et al., 2007) was used to 
generate the 3D models for αL integrin based on the x-ray structure 
of human αX integrin using the sequence alignment. The extended 
conformation of LFA-1 was obtained by adjusting the torsion angles 
at the knees of α and β subunits, and the upper and lower legs were 
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